AR117994A1 - METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN - Google Patents
METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEINInfo
- Publication number
- AR117994A1 AR117994A1 ARP200100292A ARP200100292A AR117994A1 AR 117994 A1 AR117994 A1 AR 117994A1 AR P200100292 A ARP200100292 A AR P200100292A AR P200100292 A ARP200100292 A AR P200100292A AR 117994 A1 AR117994 A1 AR 117994A1
- Authority
- AR
- Argentina
- Prior art keywords
- erbb
- mutant
- breast cancer
- negative breast
- triple negative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un método para tratar el cáncer de mama triple negativo en un sujeto, que comprende administrar una secuencia de ácidos nucleicos que codifica un polipéptido de ErbB-2 mutante en una cantidad efectiva para inhibir la proliferación de células cancerosas, en donde el ErbB-2 mutante carece de una señal de localización nuclear funcional, no puede translocarse al núcleo de la célula en la que está presente y funciona como un inhibidor dominante negativo de ErbB-2 endógeno al inhibir la translocación nuclear de ErbB-2 endógeno en la célula en la que está presente el mutante, en donde el polipéptido de ErbB-2 mutante retiene la actividad intrínseca de la tirosina quinasa y no inhibe la actividad de la tirosina quinasa de ErbB-2 endógeno.A method of treating triple negative breast cancer in a subject, comprising administering a nucleic acid sequence encoding a mutant ErbB-2 polypeptide in an amount effective to inhibit the proliferation of cancer cells, wherein the mutant ErbB-2 lacks a functional nuclear localization signal, cannot translocate to the nucleus of the cell in which it is present, and functions as a dominant negative inhibitor of endogenous ErbB-2 by inhibiting the nuclear translocation of endogenous ErbB-2 in the cell in which mutant is present, wherein the mutant ErbB-2 polypeptide retains intrinsic tyrosine kinase activity and does not inhibit endogenous ErbB-2 tyrosine kinase activity.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962801282P | 2019-02-05 | 2019-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR117994A1 true AR117994A1 (en) | 2021-09-08 |
Family
ID=70005649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200100292A AR117994A1 (en) | 2019-02-05 | 2020-02-04 | METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR117994A1 (en) |
WO (1) | WO2020161614A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2859893A1 (en) * | 2010-03-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US9427458B2 (en) * | 2010-07-22 | 2016-08-30 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet | Methods for inhibiting cancer cell proliferation |
-
2020
- 2020-02-04 AR ARP200100292A patent/AR117994A1/en unknown
- 2020-02-04 WO PCT/IB2020/050868 patent/WO2020161614A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2020161614A1 (en) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Demaria et al. | An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA | |
PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
Lu et al. | miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling | |
Kanavy et al. | Ultraviolet radiation and melanoma | |
Bian et al. | Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer | |
Song et al. | LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. | |
Liao et al. | microRNA‑32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells | |
BR112012022802A2 (en) | use of an erbb3 inhibitor, and method of suppressing cell growth and breast cancer tumor | |
SG10201908323TA (en) | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor | |
CN102154482B (en) | Application of calcium activated chloride channels ANO1/TMEM16A in diagnosis and treatment of prostate cancer | |
EA202190474A1 (en) | MICRO-RNA THERAPY AGAINST LCP-1-POSITIVE TUMORS | |
Zhang et al. | ETS-1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer | |
WO2020107002A3 (en) | Methods for expansion of natural killer (nk) cell subset and related compositions and methods | |
MX2020013535A (en) | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment. | |
de Llobet et al. | Development and characterization of an isogenic cell line with a radioresistant phenotype | |
Lu | PKM2 functions as a histone kinase | |
AR117994A1 (en) | METHODS TO TREAT TRIPLE NEGATIVE BREAST CANCER USING A HUMAN ERBB-2 MUTANT PROTEIN | |
Adane et al. | Prevalence of Coenuruscerebralis in Small Ruminants Slaughtered at Hashim Export Abattoir, Debre Zeit, Central Oromia | |
Sai et al. | Carbon-ion beam irradiation and the miR-200c mimic effectively eradicate pancreatic cancer stem cells under in vitro and in vivo conditions | |
Miao et al. | Telomere-mitochondrion links contribute to induction of senescence in MCF-7 cells after carbon-ion irradiation | |
Mansouri et al. | DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma | |
Endo et al. | The FLCN-TFE3 axis regulates macrophage activation through cellular metabolism | |
CN104611429B (en) | Application of miR-10b (micro ribonucleic acid-10b) gene to regulation of gastric cancer gene expression | |
ZHANG et al. | The effect of DRF1 silencing on the expression of MMP2 in glioma cell | |
BR112016008202A2 (en) | BREAST CANCER PROGNOSIS DETERMINATION METHODS |